Publicaciones en las que colabora con Cristina Nieto Jimenez (19)
2022
-
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer
International Journal of Molecular Sciences, Vol. 23, Núm. 10
2021
-
MZ1 co-operates with trastuzumab in HER2 positive breast cancer
Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1
-
Transcriptomic profiles of cd47 in breast tumors predict outcome and are associated with immune activation
International Journal of Molecular Sciences, Vol. 22, Núm. 8
2020
-
Checkpoint kinase 1 pharmacological inhibition synergizes with dna-damaging agents and overcomes platinum resistance in basal-like breast cancer
International Journal of Molecular Sciences, Vol. 21, Núm. 23, pp. 1-14
-
Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer
Cancer Letters, Vol. 491, pp. 50-59
-
Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer
Journal of Cellular and Molecular Medicine, Vol. 24, Núm. 5, pp. 3117-3127
2019
-
Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
Journal of Experimental and Clinical Cancer Research, Vol. 38, Núm. 1
-
Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome
OncoImmunology, Vol. 8, Núm. 10
-
Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors
PLoS ONE, Vol. 14, Núm. 4
-
Mapping Bromodomains in breast cancer and association with clinical outcome
Scientific Reports, Vol. 9, Núm. 1
-
Screening and preliminary biochemical and biological studies of [RuCl(p-cymene)(N, N-bis(diphenylphosphino)-isopropylamine)][BF4] in Breast Cancer Models
ACS Omega, Vol. 4, Núm. 8, pp. 13005-13014
2018
2017
-
BET inhibitors as novel therapeutic agents in breast cancer
Oncotarget, Vol. 8, Núm. 41, pp. 71285-71291
-
DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer
Oncotarget, Vol. 8, Núm. 38, pp. 62834-62841
-
Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors
Oncotarget, Vol. 8, Núm. 13, pp. 21733-21740
-
Neutrophils in cancer: Prognostic role and therapeutic strategies
Molecular Cancer, Vol. 16, Núm. 1
-
Synthetic lethality interaction between aurora kinases and CHEK1 inhibitors in ovarian cancer
Molecular Cancer Therapeutics, Vol. 16, Núm. 11, pp. 2552-2562
-
Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors
Oncotarget, Vol. 8, Núm. 12, pp. 19478-19490
2016
-
In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: Role of mitotic kinases
Oncotarget, Vol. 7, Núm. 16, pp. 22865-22872